RNase L activators and antisense oligonucleotides effective to treat telomerase-expressing malignancies

US6468983B2 · kind B2 · utility

Assignees

• The Cleveland Clinic Foundation · US
• The United States of America, as represented by the Department of Health and Human Services · US

Inventors

• Robert H. Silverman · Shaker Heights, US
• Seiji Kondo · Saitama, JP
• John Cowell · Augusta, US
• Guiying Li · Branford, US
• Paul F. Torrence · Gaithersburg, US

Key dates

• Filing date: Feb 3, 1998
• Grant date: Oct 22, 2002
• Expiry date: Feb 3, 2018

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2310/3183
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to chimeric molecules comprising an oligonucleotide complementary to a region of the ribonucleotide component of telomerase attached to an activator of RNase L (“activator-antisense complex”) which specifically cleaves the ribonucleotide portion of a telomerase enzyme. The present invention relates to methods of inhibiting telomerase enzymatic activity with activator-antisense complexes targeted to the RNA component of telomerase. The present invention further relates to methods of treating malignant neoplastic disease, wherein the malignant cells contain a telomerase activity that is necessary for the growth of the malignant cells.